Clinical trials: Astrocytoma
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma
- Trial name
- NCT02365662
- Testing
- ABBV-221
- Where
- 5 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- AbbVie
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00979862
- Testing
- Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Renal Cell Carcinoma
Dendritic Cell Vaccination for Patients with Solid Tumors
The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) - engineered to express the WT1 protein - in patients with limited spread…
- Conditions
- Glioblastoma, Renal Cell Carcinoma, Sarcomas, Breast Cancers
- Trial name
- NCT01291420
- Testing
- autologous dendritic cell vaccination
- Where
- Belgium
- Volunteers
- 48 people
- Sponsor
- University Hospital, Antwerp
Glioblastoma
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly…
- Trial name
- NCT02997423
- Where
- 19 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Iowa
Astrocytoma, Ganglioglioma Desmoplastics and Infantile
Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics
Astrocytomas / infantile desmoplastic gangliogliomas (DIA / DIG) are rare brain tumors usually affecting infants. They represent about 0.5% of all pediatric brain tumors.
- Trial name
- DIA/DIG (NCT03115164)
- Testing
- To study the characteristics of patients with DIA / DIG
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Adult Glioblastoma
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling.
- Trial name
- TGEN (NCT02060890)
- Testing
- specialized tumor board recommendation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Gliosarcoma
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase I/II trial studies the side effects and how well atezolizumab works in combination with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma.
- Trial name
- NCT03174197
- Testing
- Atezolizumab, Radiation Therapy, Temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Primary Brain Tumor, Glioblastoma
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia.
- Conditions
- Primary Brain Tumor, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- CBT-I in PBT (NCT06439420)
- Testing
- Cognitive Behavioral Therapy for Insomnia
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Virginia Commonwealth University
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Background: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months.
- Trial name
- NCT06419946
- Testing
- Temozolomide, Lomustine
- Where
- 20 sites in Austria, Denmark and 2 more
- Volunteers
- 200 people
- Sponsor
- Vastra Gotaland Region
Recurrent Glioblastoma (WHO-Grade IV Glioma)
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior…
- Trial name
- GliAvAx (NCT03291314)
- Testing
- Axitinib, Avelumab
- Where
- Belgium
- Volunteers
- 52 people
- Sponsor
- Universitair Ziekenhuis Brussel
Astrocytoma
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
- Trial name
- NCT03032484
- Testing
- Bevacizumab, TVB-2640
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioma, Glioblastoma
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT01478178
- Testing
- VAL-083 (Dianhydrogalactitol)
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Kintara Therapeutics, Inc.
Gliosarcoma, Recurrent Glioblastoma
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
The purpose of this research study is to evaluate the safety of the study drug, NU-0129, based on Spherical Nucleic Acid (SNA) platform when infused in patients with recurrent glioblastoma multiforme or gliosarcoma.
- Trial name
- NCT03020017
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Targeted Molecular Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme/Anaplastic Astrocytoma
Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00841555
- Testing
- temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Metastatic Cancer
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors.
- Trial name
- NCT00002647
- Testing
- verteporfin, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Glioblastoma Multiforme, Healthy Volunteers
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
- Trial name
- NCT01135875
- Testing
- GBM Patients, Normal Controls
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Florida
Glioblastomas
Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients
This study is a non-randomized, prospective, multicentric feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy…
- Trial name
- PAraDiGM (NCT03903419)
- Testing
- Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.
- Where
- 2 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Leon Berard
Malignant Glioma
D2C7-IT With Atezolizumab for Recurrent Gliomas
This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing cells, in patients with recurrent World Health…
- Trial name
- NCT04160494
- Testing
- D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Darell Bigner
Glioblastoma
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions…
- Trial name
- NCT04019262
- Testing
- Radiation Therapy, Temozolomide Oral Product
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- John Flickinger